Matteo Perrino

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Paolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri et al. · Journal of Clinical Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacotherapy +13

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

Carmine Pinto, Paolo Andrea Zucali, Maria Pagano et al. · The Lancet Oncology · 2021 · 103 citations

Medicine, Oncology, Pharmacology +12

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

Paolo Andrea Zucali, Elisa Giovannetti, Annarita Destro et al. · Clinical Cancer Research · 2011 · 100 citations

Medicine, Oncology, Pathology +17

Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

Paolo Andrea Zucali, Matteo Simonelli, G. Michetti et al. · Lung Cancer · 2011 · 94 citations

Medicine, Oncology, Pharmacotherapy +14

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna et al. · Therapeutic Advances in Medical Oncology · 2021 · 93 citations · Full text

Medicine, Immunology, Oncology +17